Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273117 | 0.79 | S1PR1 (0.40) | CYP1A2CYP2C9CYP2C19S1PR1EPHX2 | |
| SCHEMBL29616472 | 0.77 | POLQ (0.44) | CYP2C9CYP2C19EGFREPHX2GAA | |
| SCHEMBL23148999 | 0.77 | POLQ (0.44) | CYP2C9CYP2C19EGFREPHX2GAA | |
| SCHEMBL24357851 | 0.76 | LMNA (0.38) | EGFREPHX2GAA | |
| SCHEMBL274988 | 0.75 | AR (0.51) | CYP1A2CYP2C9CYP2C19S1PR1EPHX2 | |
| SCHEMBL29999042 | 0.75 | AR (0.51) | CYP1A2CYP2C9CYP2C19S1PR1EPHX2 | |
| SCHEMBL28023584 | 0.73 | S1PR1 (0.49) | CYP1A2CYP2C9CYP2C19S1PR1EPHX2 | |
| SCHEMBL11206400 | 0.73 | EGFR (0.34) | EGFREPHX2L3MBTL1 | |
| SCHEMBL6690488 | 0.72 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19S1PR1EPHX2 | |
| SCHEMBL30476348 | 0.72 | IDO1 (0.45) | EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2371822-A1 | Heterobicyclic carboxamides as inhibitors for kinases | Novartis AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2074125-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046802-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | CYP1A2 3937/4885CYP2C9 3712/4885CYP2C19 3194/4885 |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | CYP1A2 1711/4885CYP2C9 717/4885CYP2C19 827/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | CYP1A2 3257/4885CYP2C9 3940/4885CYP2C19 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.